Skip to main content
Glama

Guidetopharmacology

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.4/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Well beyond the annotations, the description discloses meaningful behavior: it fans out across many sources, returns resolved_from/resolved_to for name lookups, uses sources_used/sources_failed to distinguish 'no data' from bugs, returns resolved:false with a notes line for private companies, and treats type=company and type=ticker identically. This gives an agent an accurate mental model of the tool's behavior.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but information-dense and front-loaded with purpose and usage examples. It includes many necessary details about return sections and edge cases because there is no output schema. The structure is a bit dense/run-on, but every major clause adds functional value.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the full burden of explaining return behavior, and it does so comprehensively: it lists returned fields, source coverage, URI formats, sources_used/sources_failed semantics, empty-section meaning, input resolution behavior, and private company handling. An agent has enough context to invoke the tool correctly and interpret its response.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so the schema already documents type and value thoroughly. The description repeats these details and adds concrete examples (AAPL, 0000320193, Moderna), but does not significantly expand parameter semantics beyond what the schema provides. Baseline 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's function: producing a full cross-source profile of a US public company in one parallel call. It gives explicit example phrasings and distinguishes itself from chaining single-pack SEC/XBRL/news lookups, so an agent can tell it apart from more narrow lookup tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit when-to-use guidance: prefer this tool over chaining single-pack lookups when the user wants a holistic view, and it lists which input forms are accepted. It also notes the person/place case is not yet supported. It does not name alternative sibling tools explicitly for other scenarios, but the routing guidance is strong.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Guidetopharmacology toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Many tools have overlapping purposes, such as multiple ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) that differ only subtly, and a large set of prediction market tools (bet_research, polymarket_arbitrage, polymarket_edges, etc.) that can be easily confused. Entity tools like entity_profile, recent_changes, and compare_entities also overlap significantly. An agent would struggle to pick the right tool without careful reading.

Naming Consistency2/5

Tool names mix snake_case (ask_pipeworx, deep_research, forget) and descriptive phrases without a consistent verb_noun pattern. Some start with verbs (compare, generate, scan) while others are nouns or compound phrases (pipeworx_trending, polymarket_fill_risk). This inconsistency makes it hard to predict tool names.

Tool Count2/5

With 35 tools, this MCP server is overly large and covers many diverse domains (data querying, prediction markets, pharmacology, npm scanning, brand visibility, etc.). Typically, a well-scoped server has 5-15 tools; 35 is excessive and suggests a lack of focus, making it unwieldy for an agent to manage.

Completeness2/5

Despite the large number of tools, the server has notable gaps. For example, the pharmacology section only offers search and interaction tools but no create/update/delete. The memory tools are limited to save/recall/forget. Many meta-tools (discover_tools, suggest_questions) exist but add little substance. The server covers many domains superficially rather than providing full lifecycle coverage for any one domain.

Resources